Skip to main content

Merck revenue falls after dramatic drop in sales of Covid antiviral treatment

Despite the drop in molnupiravir sales, Merck's revenue and adjusted earnings for Q1 2023 beat Wall Street's expectations.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.